ICH E6(R3)’s Risk-Based Approach
For lean biotech and emerging biopharma teams, ICH E6(R3)’s risk-based approach is an invitation to spend deliberately. You do not need to monitor every site, data point, activity, and process with the same intensity. The goal is proportionality. To focus oversight where failure could genuinely compromise participant safety, rights, wellbeing, or the reliability of the data needed to make a development decision.
A proportional monitoring plan starts with a simple, yet clear, question: What could meaningfully derail this program? For an early-stage study, that may be informed consent, eligibility, investigational product accountability, serious adverse event reporting, endpoint assessments, or a small number of critical laboratory and imaging processes. Map those critical-to-quality factors, identify the risks to each one, and assign monitoring intensity accordingly. High-impact, high-likelihood risks deserve targeted central review, focused site visits, and rapid escalation pathways. Lower-risk activities can often be reviewed remotely, sampled periodically, or managed through trend-based signals.
The important elements are doing the work that matters most and being able to explain why. A lean team’s monitoring plan should connect directly to its protocol, operational model, service provider responsibilities, and decision-making needs. If a control does not protect a critical process or generate a signal you will act on, challenge whether it belongs in the plan.
Efficient biotechs and emerging biopharma will treat monitoring as a learning system. Review the signals, adjust where risk changes, and redeploy oversight before small operational issues become costly protocol deviations, unreliable data, or avoidable delays. That is how proportionality protects participants, preserves data integrity, and extends your runway.
If you’re working through how to translate ICH E6(R3) into practical operational readiness, let’s connect!
Where to spend limited oversight effort is a judgement call, and an expensive one to get wrong. That is the conversation behind risk-based oversight design.
